News & Events

November 15, 2022

Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities / READ MORE

January 31, 2022

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development / READ MORE

May 4, 2021

Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A. / READ MORE

October 16, 2020

Ablexis Announces Further Expansion of Its Intellectual Property on AlivaMab® Mouse and Immunoglobulin Locus Engineering / READ MORE

April 22, 2020

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies / READ MORE

September 17, 2019

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen / READ MORE

June 3, 2019

Ablexis Announces Multi-Target Licensing Agreement with Zai Lab (US) / READ MORE

January 17, 2019

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company / READ MORE

January 3, 2019

Ablexis Announces Licensing Agreement with Corvidia Therapeutics / READ MORE

December 6, 2018

Ablexis Announces Licensing Agreement with Allogene Therapeutics / READ MORE

November 13, 2018

Ablexis Announces Progress in Its Intellectual Property on AlivaMab Mouse and Immunoglobulin Locus Engineering / READ MORE

November 5, 2018

Ablexis Announces Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development / READ MORE

October 23, 2018

Ablexis Announces Licensing Agreement with Voyager Therapeutics / READ MORE

October 9, 2018

Ablexis Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center / READ MORE

June 21, 2018

Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services / READ MORE

Conferences

PEGS Europe

November 14-16, 2022, Barcelona, Spain

Antibody Engineering and Therapeutics

December 4-8, 2022; San Diego, California

J.P. Morgan 41st Annual Healthcare Conference

January 9-12, 2023.  San Francisco, California

On-demand Webinars

Begin with the End in Mind: Selection of an Antibody Discovery Platform

How the choice of therapeutic antibody discovery platform can impact downstream success in development and the market

Register

Articles

Featured in Nature Biopharma Dealmakers
Ablexis and AlivaMab Discovery Services

Unparalleled success in antibody discovery and development

Download PDF